文献速递胃肠外科围术期管理与 ERAS

胃癌全胃切除术后90天死亡率分析

Ninety-day mortality after total gastrectomy for gastric cancer.
PubMed 文献 · Surgery · 2021-03-28

基于美国国家癌症数据库2004-2015年数据,5484例I-III期胃腺癌全胃切除术患者中,90天死亡率为9.1%,30天死亡率为4.7%,近半数90天内死亡发生在术后30天之后。多因素分析显示高龄、低收入、Charlson-Deyo评分≥2、低容量中心、N分期、淋巴结检出<16枚及未接受化疗与90天死亡率相关,90天死亡率从2004年14.3%显著降至2015年7.9%。

要点

  • 全胃切除术后90天死亡率9.1%,近半数死亡发生在30天之后。
  • N分期越高、淋巴结检出<16枚及未化疗者90天死亡风险显著增加。
  • 90天死亡率从2004年14.3%降至2015年7.9%,但仍需加强出院后照护。

核心结论

  • 胃癌全胃切除术后近半数90天内死亡发生在术后30天之后,90天死亡率随时间改善但仍较高。

研究设计与样本

  • 回顾性分析美国国家癌症数据库2004-2015年5484例I-III期胃腺癌全胃切除术患者,采用多因素logistic回归分析死亡预测因素,Joinpoint回归计算年趋势。

主要发现

  • 90天死亡率为9.1%,30天死亡率为4.7%。
  • 90天死亡相关因素包括年龄增长(OR 1.0,P<.001)、收入低于中位数(OR 1.2,P=.039)、Charlson-Deyo评分≥2(OR 1.4,P=.039)、低容量中心治疗(OR 1.5,P<.001)、N1(OR 2.0,P<.001)、N2(OR 2.0,P<.001)、N3(OR 2.7,P<.001)、淋巴结检出<16枚(OR 1.5,P<.001)及未接受化疗(OR 3.7,P<.001)。
  • 无保险(OR 4.1,P=.080)和切缘阳性(OR 1.3,P=.080)与90天死亡相关但无统计学显著性。
  • 90天死亡率从2004年14.3%显著降至2015年7.9%(P=.006),30天死亡率从2004年7.7%显著降至2015年4.8%(P=.009)。

临床怎么用

  • 全胃切除术后应关注30天之后的出院后照护,尤其对高龄、低收入、合并症多、N分期高、淋巴结检出不足及未化疗患者加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total gastrectomy for gastric cancer is associated with significant 30-day mortality, but this endpoint may underestimate the short-term mortality of the procedure. METHODS: Retrospective analysis was performed using the National Cancer Database (2004-2015). Patients who underwent total gastrectomy for stage I to III gastric adenocarcinoma were identified and divided into cohorts based on 90-day mortality. Predictors of mortality were analyzed using multivariable logistic regression, and annual trends in mortality rates were calculated by Joinpoint Regression. RESULTS: Of the 5,484 patients who underwent total gastrectomy, 90-day and 30-day mortality rates were 9.1% and 4.7%, respectively. Factors associated with 90-day mortality included increasing age (odds ratio 1.0, P < .001), income below the median (odds ratio 1.2, P = .039), Charlson-Deyo score ≥2 (odds ratio 1.4, P = .039), treatment at low-volume facilities (odds ratio 1.5, P < .001), N1 (odds ratio 2.0, P < .001), N2 (odds ratio 2.0, P < .001), or N3 (odds ratio 2.7, P < .001) stage disease, having <16 lymph nodes harvested (odds ratio 1.5, P < .001), and lack of treatment with chemotherapy (3.7, P < .001). Lack of health insurance (odds ratio 4.1, P = .080), and positive microscopic margins (odds ratio 1.3, P = .080) were correlated, but not significantly associated, with 90-day mortality. The 90-day mortality rate significantly declined from 14.3% in 2004 to 7.9% in 2015 (P = .006), and the 30-day mortality rate significantly declined from 7.7% in 2004 to 4.8% in 2015 (P = .009). CONCLUSION: Nearly half of the deaths within 90 days after total gastrectomy for cancer occur beyond 30 days postoperative. Ninety-day mortality has improved over time, but rates remain high, suggesting the need for improved out-of-hospital postoperative care beyond 30 days.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Shannon AB, Straker RJ, Fraker DL, et al. Ninety-day mortality after total gastrectomy for gastric cancer. Surgery. 2021. PMID: 33789812. doi:10.1016/j.surg.2021.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。